BioSkryb Genomics
PrivateLast Round
Series A
May 1, 2025
Total Funding Raised
$31.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
BioSkryb Genomics is a biotechnology company that develops a genome amplification system leveraging cellular heterogeneity to provide scientists and clinicians with comprehensive insights into the genome, transcriptome, and proteome of individual cells for the study of complex diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioSkryb Genomics Comparables
Compare BioSkryb Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mission Bio | 83% | |
| Xingeyuan Biotechnology | 79% | |
| Atrandi Biosciences | 79% |
BioSkryb Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 1, 2025 | ||||
| Seed | Jan 9, 2020 |
Key People
Founding team and executive leadership
BioSkryb Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Anzu Partners | Series A, Seed |
| Wilson Sonsini Goodrich & Rosati | Seed, Series A |
| Seed Healthcare | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 42% MoM, reaching 7.7K.
- Jul 28, 2026
Monthly visitors increased 37% MoM.
Recent news
Latest coverage and updates
- hiresAug 19, 2026
BioSkryb Genomics, Inc. hired Evans as Chief Executive Officer on Aug 19th '26.
- promotesAug 19, 2026
BioSkryb Genomics, Inc. promoted Bill to CEO on Aug 19th '26.
- hiresAug 19, 2026
BioSkryb Genomics, Inc. hired William E. Evans as Chief Executive Officer on Aug 19th '26.
BioSkryb Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BioSkryb Genomics's valuation, stock price, and market status.
Is Bioskryb a public or private company?
Bioskryb is a private company.
What is the current stock price of Bioskryb?
Bioskryb is a private company with no public stock price. No recent secondary market data is available.
How much is Bioskryb worth (valuation)?
Valuation information for Bioskryb is not publicly available.
Can I buy Bioskryb stock?
Bioskryb shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Bioskryb's last funding round?
Bioskryb's most recent funding round was Series A on May 1, 2025.
Who are the main investors in Bioskryb?
Key investors in Bioskryb include Anzu Partners.
Will Bioskryb IPO soon?
No public IPO plans have been announced for Bioskryb.
How can I track Bioskryb secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bioskryb's secondary market activity and sign up for updates.